Investment Bank Downgrades Luminex, Qiagen Stocks | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

Analysts Doug Schenkel and Shaun Rodriguez wrote in a research note published today that concerns about competition and a lack of "significant near-term catalysts" has led them to downgrade Luminex. "We believe competitive pressures have intensified for [Luminex's] molecular diagnostics franchise and anticipate pronounced share loss in [Respiratory Virus Panel] and a muted [Gastrointestinal Pathogen Panel] launch as a result."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.